Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

2.

Metabolic syndrome in mental illness: evidence and way out.

Saddichha S.

Int J Clin Pharmacol Ther. 2010 Jan;48(1):84-6. No abstract available.

PMID:
20040344
3.

Metabolic effects associated with atypical antipsychotic medications.

Antai-Otong D.

Perspect Psychiatr Care. 2004 Apr-Jun;40(2):70-2. Review.

PMID:
15323415
4.

Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications.

Hasnain M, Vieweg WV, Fredrickson SK, Beatty-Brooks M, Fernandez A, Pandurangi AK.

Prim Care Diabetes. 2009 Feb;3(1):5-15. doi: 10.1016/j.pcd.2008.10.005. Epub 2008 Dec 10. Review.

PMID:
19083283
5.

Assessment of a point-of-care metabolic risk screening program in outpatients receiving antipsychotic agents.

Schneiderhan ME, Batscha CL, Rosen C.

Pharmacotherapy. 2009 Aug;29(8):975-87. doi: 10.1592/phco.29.8.975.

PMID:
19637951
6.

When essential medications provoke new health problems: the metabolic effects of second-generation antipsychotics.

Stein K.

J Am Diet Assoc. 2010 Jul;110(7):992-1001. doi: 10.1016/j.jada.2010.05.015. No abstract available.

PMID:
20630154
7.

[Reaction on 'Antipsychotics and metabolic abnormalities in children and adolescents; a review of the literature and some recommendations'].

Cohen D, de Hert M.

Tijdschr Psychiatr. 2010;52(8):605-7; author reply 608. Dutch. No abstract available.

8.

Metabolic side effects of second-generation antipsychotics in children and adolescents: a different story?

Correll CU.

J Clin Psychiatry. 2005 Oct;66(10):1331-2. No abstract available.

PMID:
16259549
9.

Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome.

Shirzadi AA, Ghaemi SN.

Harv Rev Psychiatry. 2006 May-Jun;14(3):152-64. Review.

PMID:
16787887
10.

Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.

Stargardt T, Weinbrenner S, Busse R, Juckel G, Gericke CA.

J Ment Health Policy Econ. 2008 Jun;11(2):89-97.

PMID:
18509216
11.

Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.

Goodwin G, Fleischhacker W, Arango C, Baumann P, Davidson M, de Hert M, Falkai P, Kapur S, Leucht S, Licht R, Naber D, O'Keane V, Papakostas G, Vieta E, Zohar J.

Eur Neuropsychopharmacol. 2009 Jul;19(7):520-32. doi: 10.1016/j.euroneuro.2009.04.003. Epub 2009 May 2.

PMID:
19411165
12.

Differential pharmacology of atypical antipsychotics: clinical implications.

Masand PS.

Am J Health Syst Pharm. 2007 Jan 15;64(2 Suppl 1):S3-8; quiz S24-5.

PMID:
17215475
13.

[Atypical antipsychotics and metabolic syndrome].

Baranyi A, Yazdani R, Haas-Krammer A, Stepan A, Kapfhammer HP, Rothenhäusler HB.

Wien Med Wochenschr. 2007;157(11-12):255-70. Review. German.

PMID:
17915438
14.

Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents.

Correll CU, Penzner JB, Parikh UH, Mughal T, Javed T, Carbon M, Malhotra AK.

Child Adolesc Psychiatr Clin N Am. 2006 Jan;15(1):177-206. Review.

PMID:
16321730
15.

Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients.

Morrato EH, Cuffel B, Newcomer JW, Lombardo I, Kamat S, Barron J.

J Clin Psychopharmacol. 2009 Feb;29(1):26-32. doi: 10.1097/JCP.0b013e31819294cb.

PMID:
19142103
16.

Second-generation antipsychotics and the metabolic syndrome.

Masand PS, Mago R.

Curr Psychiatry Rep. 2005 Jun;7(3):153-4. No abstract available.

PMID:
15935125
17.

Identifying metabolic risks with antipsychotics and monitoring and management strategies.

Newcomer JW, Sernyak MJ.

J Clin Psychiatry. 2007 Jul;68(7):e17. Review.

18.

Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents.

McIntyre RS, Jerrell JM.

Arch Pediatr Adolesc Med. 2008 Oct;162(10):929-35. doi: 10.1001/archpedi.162.10.929.

PMID:
18838645
19.

[Schizophrenia and antipsychotics associated with the metabolic syndrome. An overview].

Scheepers-Hoeks AM, Wessels-Basten SJ, Scherders MJ, Bravenboer B, Loonen AJ, Kleppe RT, Grouls RJ.

Tijdschr Psychiatr. 2008;50(10):645-54. Review. Dutch.

20.

Supplemental Content

Support Center